Expression of the galectin-9‑Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma

Liu,Zengjin; Han,Huamin; He,Xin; Li,Shouwei; Wu,Chenxing; Yu,Chunjiang; Wang,Shengdian

doi:10.3892/ol.2016.4142

Expression of the galectin-9‑Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma

Authors:
- Zengjin Liu
- Huamin Han
- Xin He
- Shouwei Li
- Chenxing Wu
- Chunjiang Yu
- Shengdian Wang
View Affiliations

Affiliations: Department of Neurosurgery, Beijing Sanbo Brain Hospital, Capital Medical University, Beijing 100093, P.R. China, Key Laboratory of Infection and Immunity, Institute of Biophysics, University of Chinese Academy of Sciences, Beijing 100101, P.R. China
Published online on: January 26, 2016 https://doi.org/10.3892/ol.2016.4142
Pages: 1829-1834

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma is known to induce local and systemic immunosuppression, which inhibits antitumor T cell responses. The galectin‑9‑Tim‑3‑pathway negatively regulates T cell pathways in the tumor immunosuppressive environment. The present study assessed the expression of Tim‑3 and galectin‑9 in glioma patients, and evaluated the association between the expression of Tim‑3 and galectin‑9 with clinical characteristics. The present study identified that Tim‑3 expression was significantly increased in peripheral blood T cells of glioma patients compared with those of healthy controls, and was additionally increased on tumor‑infiltrating T cells. The expression of Tim‑3 on tumor‑infiltrating T cells was associated with the World Health Organization (WHO) grade of glioma, but negatively correlated with the Karnofsky Performance Status score of the glioma patients. Immunohistochemical analysis revealed that the expression of galectin‑9 in tumor tissues was associated with Tim‑3 expression on tumor‑infiltrating T cells and the WHO grade of glioma. These findings suggest that the galectin‑9‑Tim‑3 pathway may be critical in the immunoevasion of glioma and may be a potent target for immunotherapy in glioma patients.

View Figures

View References

1	Liu Y, Shete S, Hosking F, Robertson L, Houlston R and Bondy M: Genetic advances in glioma: Susceptibility genes and networks. Curr Opin Genet Dev. 20:239–244. 2010. View Article : Google Scholar : PubMed/NCBI
2	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
3	Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, Ueda R and Fujita M: Immunotherapeutic approaches for glioma. Crit Rev Immunol. 29:1–42. 2009. View Article : Google Scholar : PubMed/NCBI
4	Flies DB, Sandler BJ, Sznol M and Chen L: Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med. 84:409–421. 2011.PubMed/NCBI
5	Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
6	Koguchi K, Anderson DE, Yang L, O'Connor KC, Kuchroo VK and Hafler DA: Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med. 203:1413–1418. 2006. View Article : Google Scholar : PubMed/NCBI
7	Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 6:1245–1252. 2005. View Article : Google Scholar : PubMed/NCBI
8	Ju Y, Hou N, Meng J, Wang X, Zhang X, Zhao D, Liu Y, Zhu F, Zhang L, Sun W, et al: T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol. 52:322–329. 2010. View Article : Google Scholar : PubMed/NCBI
9	Lemke D, Pfenning PN, Sahm F, Klein AC, Kempf T, Warnken U, Schnölzer M, Tudoran R, Weller M, Platten M and Wick W: Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. Clin Cancer Res. 18:105–117. 2012. View Article : Google Scholar : PubMed/NCBI
10	Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, Cheng Y, Kim JW, Qiao J, Zhang L, et al: Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 20:5290–5301. 2014. View Article : Google Scholar : PubMed/NCBI
11	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
12	De Groot CJ, Montagne L, Janssen I, Ravid R, Van Der Valk P and Veerhuis R: Isolation and characterization of adult microglial cells and oligodendrocytes derived from postmortem human brain tissue. Brain Res Brain Res Protoc. 5:85–94. 2000. View Article : Google Scholar : PubMed/NCBI
13	Olah M, Raj D, Brouwer N, De Haas AH, Eggen BJ, Den Dunnen WF, Biber KP and Boddeke HW: An optimized protocol for the acute isolation of human microglia from autopsy brain samples. Glia. 60:96–111. 2012. View Article : Google Scholar : PubMed/NCBI
14	Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 12:395–402. 2007. View Article : Google Scholar : PubMed/NCBI
15	Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ and Gandara DR: SWOG: Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 26:4771–4776. 2008. View Article : Google Scholar : PubMed/NCBI
16	Wang L, He S, Tu Y, Ji P, Zong J, Zhang J, Feng F, Zhao J, Gao G and Zhang Y: Downregulation of chromatin remodeling factor CHD5 is associated with a poor prognosis in human glioma. J Clin Neurosci. 20:958–963. 2013. View Article : Google Scholar : PubMed/NCBI
17	Ji Y, Wei Y, Wang J, Ao Q, Gong K and Zuo H: Decreased expression of microRNA-107 predicts poorer prognosis in glioma. Tumour Biol. 36:4461–4466. 2015. View Article : Google Scholar : PubMed/NCBI
18	Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, et al: Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 415:536–541. 2002. View Article : Google Scholar : PubMed/NCBI
19	Asakura H, Kashio Y, Nakamura K, Seki M, Dai S, Shirato Y, Abedin MJ, Yoshida N, Nishi N, Imaizumi T, et al: Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. J Immunol. 169:5912–5918. 2002. View Article : Google Scholar : PubMed/NCBI
20	Park WS, Jung WK, Park SK, Heo KW, Kang MS, Choi YH, Kim GY, Park SG, Seo SK, Yea SS, et al: Expression of galectin-9 by IFN-γ stimulated human nasal polyp fibroblasts through MAPK, PI3K, and JAK/STAT signaling pathways. Biochem Biophys Res Commun. 411:259–264. 2011. View Article : Google Scholar : PubMed/NCBI
21	Ungerer C, Quade-Lyssy P, Radeke HH, Henschler R, Königs C, Köhl U, Seifried E and Schüttrumpf J: Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations. Stem Cells Dev. 23:755–766. 2014. View Article : Google Scholar : PubMed/NCBI
22	Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW, Hirashima M, et al: Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 318:1141–1143. 2007. View Article : Google Scholar : PubMed/NCBI
23	Rolle CE, Sengupta S and Lesniak MS: Mechanisms of immune evasion by gliomas. Adv Exp Med Biol. 746:53–76. 2012. View Article : Google Scholar : PubMed/NCBI
24	Anderson AC: Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol. 24:213–216. 2012. View Article : Google Scholar : PubMed/NCBI
25	Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V and Zarour HM: Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 207:2175–2186. 2010. View Article : Google Scholar : PubMed/NCBI
26	Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK and Anderson AC: Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 207:2187–2194. 2010. View Article : Google Scholar : PubMed/NCBI
27	Baitsch L, Baumgaertner P, Devêvre E, Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplancke B, Romero P, et al: Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J Clin Invest. 121:2350–2360. 2011. View Article : Google Scholar : PubMed/NCBI
28	Calinescu AA, Kamran N, Baker G, Mineharu Y, Lowenstein PR and Castro MG: Overview of current immunotherapeutic strategies for glioma. Immunotherapy. 7:1073–1104. 2015. View Article : Google Scholar : PubMed/NCBI